CSPS Fellow Recipients
Dr. Fakhreddin (Mo) Jamali
Dr. Jamali is recognized internationally as one of the most accomplished Canadian academics in pharmacokinetics/pharmacodynamics. More specifically, he has attained an exceptional reputation in the stereochemical aspects of Drug action, effects of pathophysiological states on the action/disposition of Drugs, clinical pharmacology of anti-rheumatic, analgesic and cardiovascular agents, and in the toxicology of non-steroidal anti-inflammatory Drugs (NSAIDs). Embedded throughout his research themes is a common thread – translation of research studies into direct clinical applications. Scholarly output has been prolific with some 200 peer-reviewed publications and over 250 research abstracts.
Dr.. Jamali’s pursuit of scientific exploration is relentless. At the most fundamental level, he has an innate aptitude to look at issues tangentially. For example, he conducted innovative and insightful investigations on the stereochemical implications of NSAID development, disposition, action and safety and, more recently, the significance of inflammation on Drug pharmacokinetics and dynamics. These investigations have been pioneering, at the forefront of scholarship and have advanced the international scientific and clinical understanding in these areas.
Dr. Jamali was the founding father and creative force behind the Canadian Society for Pharmaceutical Sciences, as well as the founding father of the first-in-the-field, free and open access peer-reviewed online pharmaceutical journal, the Journal of Pharmacy and Pharmaceutical Sciences.
Dr. Iain McGilveray
Dr. McGilveray began working in the Department of National Health and Welfare, now Health Canada, as a Research Scientist in 1966 and by 1969 became involved with the emerging discipline of biopharmaceutics and pharmacokinetics. Highlights of his work included factors affecting acetaminophen kinetics, human metabolism of theophylline; study of dose dependent kinetics of prednisone, phenylbutazone and their metabolites and numerous bioavailability and dissolution studies. In the Bioanalytical area, he contributed advances in the plasma level determination of corticosteroids, phenothiazines, digoxin and cyclosporine. He was involved with new Drug submissions, providing evaluation of pharmacokinetic and metabolism sections as well as for IND study protocols. He has contributed over 157 research publications.
After retirement from Health Canada at the end of 1997 he became a consultant to the pharmaceutical industry. He was subsequently appointed Adjunct Professor, Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, and still contributes to ongoing research.
During his entire career, Dr. McGilveray has been involved internationally and is the recipient of more than a few awards.
At the inaugural meeting of the Canadian Society for Pharmaceutical Sciences (February, 1998) the symposium was dedicated to Dr. McGilveray who was presented with the first CSPS Achievement Award “for his Outstanding Leadership in Regulatory Pharmaceutical Sciences”.
Dr. Robert Young
Robert Young brings almost 30 years of pharmaceutical industry experience to academia where he is reengineering the thinking about approaches to drug discovery and design. His career and achievements make him one of the most accomplished medicinal chemists in Canada. Among his achievements is the discovery and development of Singulair®, a breakthrough drug for the treatment of asthma and seasonal allergic rhinitis.